All
FDA Approves Itovebi Combo for Some With Advanced Breast Cancer
Published: October 10th 2024 | Updated: October 11th 2024The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) for certain patients with advanced or metastatic breast cancer.